Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11365504 | 0.82 | GABRR1 (0.42) | CYP1A2GABRR1NAALAD2FOLH1ENPEP | |
| SCHEMBL10960652 | 0.79 | GABRR1 (0.37) | CYP1A2GABRR1NAALAD2FOLH1ENPEP | |
| SCHEMBL250969 | 0.79 | GABRR1 (0.44) | CYP1A2GABRR1NAALAD2FOLH1ENPEP | |
| SCHEMBL5539684 | 0.79 | GABRR1 (0.44) | CYP1A2GABRR1NAALAD2FOLH1ENPEP | |
| SCHEMBL16749901 | 0.79 | GABRR1 (0.44) | CYP1A2GABRR1NAALAD2FOLH1ENPEP | |
| SCHEMBL27335599 | 0.78 | GABRR1 (0.39) | CYP1A2GABRR1NAALAD2FOLH1ENPEP | |
| SCHEMBL22396499 | 0.77 | GABRR1 (0.42) | CYP1A2GABRR1NAALAD2FOLH1ENPEP | |
| SCHEMBL25660349 | 0.77 | GABRR1 (0.42) | CYP1A2GABRR1NAALAD2FOLH1ENPEP | |
| SCHEMBL4450853 | 0.77 | GABRR1 (0.42) | CYP1A2GABRR1NAALAD2FOLH1ENPEP | |
| SCHEMBL15905686 | 0.75 | GABRR1 (0.41) | CYP1A2GABRR1NAALAD2FOLH1ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812381-B1 | ETHYLENICALLY UNSATURATED GROUP-CONTAINING ISOCYANATE COMPOUND AND PROCESS FOR PRODUCING THE SAME, AND REACTIVE MONOMER, REACTIVE (METH)ACRYLATE POLYMER AND ITS USE | SHOWA DENKO KK (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-7579066-B2 | Ethylenically unsaturated group-containing isocyanate compound and process for producing the same, and reactive monomer, reactive (meth) acrylate polymer and its use | SHOWA DENKO K.K. (JP) | 2009-08-25 | — | — | US | disclosed |
| US-20080132597-A1 | Ethylenically Unsaturated Group-Containing Isocyanate Compound and Process for Producing the Same, and Reactive Monomer, Reactive (Meth) Acrylate Polymer and its Use | RESONAC CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| US-4520209-A | Process for cyclizing upsilon-chlorocarboxylic acids | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1985-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132597-A1 | Ethylenically Unsaturated Group-Containing Isocyanate Compound and Process for Producing the Same, and Reactive Monomer, Reactive (Meth) Acrylate Polymer and its Use | ACAD9, ELOVL6, ELOVL5 | CYP1A2 296/4885GABRR1 2290/4885NAALAD2 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.